Clinical trials and drug cost savings for Italian health service.
Clinical trials
Cost reduction
Cost savings
Drugs expenditure
Investigational drug
Per-patient cost
Treatment costs
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
26 Nov 2020
26 Nov 2020
Historique:
received:
21
06
2020
accepted:
15
11
2020
entrez:
27
11
2020
pubmed:
28
11
2020
medline:
15
5
2021
Statut:
epublish
Résumé
The cost of anticancer drugs is constantly growing. The aim of this study was determine the impact in terms of cost reduction for anticancer drug in the Italian Health Service due to patient participation in clinical trials. We evaluated the cost of drugs administered to patients treated in clinical trials at the National Cancer Institute of Naples in a four-week time period. Patients with a diagnosis of different cancers were considered, including adjuvant therapy and treatment for advanced disease, pharma sponsored and investigator initiated phase I, II and III clinical studies. We defined the expected standard treatment for each patient and we calculated the cost of the standard antineoplastic drugs that should be administered in clinical practice outside clinical trials. We used the market price of drugs to determine the cost savings value. Costs other than drugs were not included in the cost saving calculation. From 23.10.2017 to 17.11.2017, 126 patients were treated in 34 pharma sponsored and investigator initiated clinical trials, using experimental drugs provided free of charge by the sponsors, for an overall number of 152 cycles of therapy. If these patients were treated with conventional therapies in clinical practice the cost of antineoplastic drugs would account for 517,658 Euros, with an average of 5487 Euros saved per patients for a period of 4 weeks. Clinical trials with investigational antineoplastic drugs provided free of charge by Sponsors render considerable cost savings, with a tangible benefit in clinical and administrative strategies to reduce drug expenditures.
Sections du résumé
BACKGROUND
BACKGROUND
The cost of anticancer drugs is constantly growing. The aim of this study was determine the impact in terms of cost reduction for anticancer drug in the Italian Health Service due to patient participation in clinical trials.
METHODS
METHODS
We evaluated the cost of drugs administered to patients treated in clinical trials at the National Cancer Institute of Naples in a four-week time period. Patients with a diagnosis of different cancers were considered, including adjuvant therapy and treatment for advanced disease, pharma sponsored and investigator initiated phase I, II and III clinical studies. We defined the expected standard treatment for each patient and we calculated the cost of the standard antineoplastic drugs that should be administered in clinical practice outside clinical trials. We used the market price of drugs to determine the cost savings value. Costs other than drugs were not included in the cost saving calculation.
RESULTS
RESULTS
From 23.10.2017 to 17.11.2017, 126 patients were treated in 34 pharma sponsored and investigator initiated clinical trials, using experimental drugs provided free of charge by the sponsors, for an overall number of 152 cycles of therapy. If these patients were treated with conventional therapies in clinical practice the cost of antineoplastic drugs would account for 517,658 Euros, with an average of 5487 Euros saved per patients for a period of 4 weeks.
CONCLUSIONS
CONCLUSIONS
Clinical trials with investigational antineoplastic drugs provided free of charge by Sponsors render considerable cost savings, with a tangible benefit in clinical and administrative strategies to reduce drug expenditures.
Identifiants
pubmed: 33243262
doi: 10.1186/s12913-020-05928-6
pii: 10.1186/s12913-020-05928-6
pmc: PMC7691104
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1089Références
J Oncol Pharm Pract. 2019 Jul;25(5):1099-1104
pubmed: 29792122
Am J Health Syst Pharm. 2004 Jan 1;61(1):27-32
pubmed: 14725117
Br J Cancer. 2013 Oct 15;109(8):2051-7
pubmed: 24064969
Actas Urol Esp. 2015 Nov;39(9):553-7
pubmed: 26071987
Health Care Manage Rev. 2008 Apr-Jun;33(2):103-12
pubmed: 18360161
Health Aff (Millwood). 2008 Sep-Oct;27(5):1353-6
pubmed: 18780924
Am J Health Syst Pharm. 2000 Jan 1;57(1):40-3
pubmed: 10630555
Lung Cancer. 2013 Aug;81(2):236-40
pubmed: 23648072
PLoS One. 2019 Jan 8;14(1):e0210330
pubmed: 30620767